NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









CytoReason

CytoReason

Private
Tel AvivHealthcare & Life Scienceshttps://cytoreason.com/

Last Round

Debt

Jul 17, 2024

Total Funding Raised

$152M

Company Overview

CytoReason is a biotechnology company that offers cell-based models and data analysis services to create computational models of the human body for simulating diseases at the cellular level.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Medical AI, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

drug discoverydisease simulationin silico drug discoverymulti-omic datacomputational biologyclinical trial designpatient stratificationtarget identificationAI drug discoverydigital twinbiotech AIpredictive modelingdata as a serviceDaaS

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

CytoReason Comparables

Compare CytoReason with similar companies based on industry and business-model similarity.

CytoReason comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Aitia
82%
Insilico Medicine
82%
Protai
79%

CytoReason Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
DebtJul 17, 2024
StrategicSep 20, 2022
Series AJun 1, 2021
SeedJan 1, 2020

Key People

Founding team and executive leadership

David H.

Co-Founder And CEO

Founding Team

Elad Peleg

COO And CFO

Executive Team

CytoReason Investors

Notable investors and investment history

CytoReason investors
InvestorRounds
Pontifax Venture CapitalSeed
Pico Venture PartnersSeries A, Seed
PfizerDebt, Strategic
Bank HapoalimDebt

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 15, 2026

    Launched new product at the JPM HealthCare Conference 2026.

  • Jan 15, 2026

    Launched an AI chat-style assistant for pharma R&D.

CytoReason Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

CytoReason Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about CytoReason's valuation, stock price, and market status.

Firmographic Details

HeadquartersTel Aviv
Employee Range116
Year Founded2016
Last FundingJul 17, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.